Washington, DC - December 11, 2008 - The following is GlaxoSmithKline's [NYSE: GSK] statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines ...
Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy ...
This was a prospective, randomised, double-blind, double-dummy, parallel-group, multicentre study conducted in 36 primary-care centres in Sweden in accordance with the 1996 Declaration of Helsinki.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results